To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests
Institute of Clinical Chemistry, Bern University Hospital, Bern, Switzerland.
Institute of Clinical Physiology, CNR, Pisa, Italy.
Örebro University, School of Science and Technology.ORCID iD: 0000-0002-4382-4355
OWL Metabolomics, Bizkaia Technology Park, Derio, Spain.
Show others and affiliations
2021 (English)In: Nature Reviews. Gastroenterology & Hepatology, ISSN 1759-5045, E-ISSN 1759-5053, Vol. 18, no 12, p. 835-856Article, review/survey (Refereed) Published
Abstract [en]

Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is often associated with aspects of metabolic syndrome. Despite its prevalence and the importance of early diagnosis, there is a lack of robustly validated biomarkers for diagnosis, prognosis and monitoring of disease progression in response to a given treatment. In this Review, we provide an overview of the contribution of metabolomics and lipidomics in clinical studies to identify biomarkers associated with NAFLD and nonalcoholic steatohepatitis (NASH). In addition, we highlight the key metabolic pathways in NAFLD and NASH that have been identified by metabolomics and lipidomics approaches and could potentially be used as biomarkers for non-invasive diagnostic tests. Overall, the studies demonstrated alterations in amino acid metabolism and several aspects of lipid metabolism including circulating fatty acids, triglycerides, phospholipids and bile acids. Although we report several studies that identified potential biomarkers, few have been validated.

Place, publisher, year, edition, pages
Nature Publishing Group, 2021. Vol. 18, no 12, p. 835-856
National Category
Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:oru:diva-94280DOI: 10.1038/s41575-021-00502-9ISI: 000694785900001PubMedID: 34508238Scopus ID: 2-s2.0-85114988963OAI: oai:DiVA.org:oru-94280DiVA, id: diva2:1593325
Funder
EU, Horizon 2020, 634413
Note

Funding agencies:

Innovative Medicines Initiative 2 Joint Undertaking under the LITMUS project 777377

Swiss National Science Foundation (SNSF) 190686

EFPIA

Available from: 2021-09-12 Created: 2021-09-12 Last updated: 2025-02-11Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Hyötyläinen, TuuliaOresic, Matej

Search in DiVA

By author/editor
Hyötyläinen, TuuliaOresic, Matej
By organisation
School of Science and TechnologySchool of Medical Sciences
In the same journal
Nature Reviews. Gastroenterology & Hepatology
Gastroenterology and Hepatology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 127 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf